Nominations for the 2012 Award are now closed.
The Award and Lecture
AACR and Eli Lilly and Company established this award in 1961 to honor Dr. G.H.A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The Clowes Award recognizes an individual with outstanding recent accomplishments in basic cancer research.
The winner of the 52nd Annual AACR G.H.A. Clowes Memorial Award will receive a $10,000 honorarium, give a 50-minute lecture during the AACR 103rd Annual Meeting 2012 in Chicago, IL USA (March 31-April 4, 2012), and be given support for the winner and a guest to attend the Annual Meeting. The winner will also speak at the Eli Lilly and Company headquarters in Indianapolis, Indiana, at the invitation of the company later in 2012.
Eligibility
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nomination Procedure and Instructions
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nominations must be submitted online at https://proposalcentral.altum.com/, no later than 4:00 p.m. United States Eastern Standard Time on Friday, October 14, 2011. Paper nominations will not be accepted. Full program guidelines and nomination instructions are available through the link below and on the proposalCentral website.
Selection
Candidates will be considered by a committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the Award Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate’s recent accomplishments in basic cancer research. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Supporter
Generously supported by Eli Lilly and Company.
Questions?
Linda Brooks-Stokes, Program Associate
linda.stokes@aacr.org
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
SPOTLIGHT
|
51st Annual Recipient
Yosef Shiloh, Ph.D.
Myers Professor of Cancer Genetics and Professor of Human Molecular Genetics and Biochemistry
Sackler School of Medicine
Tel Aviv University
Tel Aviv, Israel
|
Dr. Yosef Shiloh delivered his award lecture entitled, Mining rare genetic disorders for new insights into human biology: lessons from ataxia-telangiectasia, at the AACR 102nd Annual Meeting 2011 in Orlando, FL. The award was presented by Dr. Jonathan M. Yingling of Eli Lilly and Company and Dr. Guillermina Lozano, Selection Committee chairperson.
_______________________________________________________________________________________
Dr. Shiloh is an international leader in the study of Ataxia-Telangiectasia(A-T), and his identification and cloning of the A-T gene provided for the first time a definitive diagnosis for so many who had gone without one. This discovery, along with his subsequent work, has played a critical role in increasing our understanding of DNA damage response and repair, which has important implications for cancer causation and cancer therapy, as well as other diseases.
Patients with A-T exhibit progressive neurodegeneration, immunodeficiency, striking cancer predisposition and chromosomal fragility. The disease is caused by a profound defect in a major mechanism that maintains genomic stability - the cellular response to DNA double strand breaks. For over 30 years Dr. Shiloh has been investigating A-T and the defect in the DNA damage response that leads to this disease. He changed the field when his lab identified the A-T gene in 1995 and successfully cloned it, calling it ataxia-telangiectasia mutated (ATM). The identification of the ATM gene revolutionized the field, opening many new avenues of inquiry and allowing research to race forward.
Dr. Shiloh's laboratory has expanded its studies to the mode of action of the ATM gene product - the ATM protein kinase - and the extensive signaling network that it activates in response to DNA damage. A leader in this field, Dr. Shiloh's work has made a major impact on the scientific understanding of the cellular response to genotoxic stress. This, in turn, has led to the discovery of many new genes, proteins and processes with critical roles in human biology and cancer.
From 1983 to 1985 he was a research fellow at Harvard Medical School and The Children's Hospital of Boston. He joined Tel Aviv University in 1985 as a senior lecturer of human genetics and was an associate professor there from 1989 to 1995. He has been a professor of human genetics at Tel Aviv University Sackler School of Medicine since 1995 and served as chairman of the department of human genetics and molecular medicine from 2002 through 2005.